| Name | Title | Contact Details |
|---|---|---|
Rick Hensley |
Director of Risk Management and Physical Security | Profile |
John Marcellus |
Director of Information Technology Operations | Profile |
Care Axis is a Newcastle, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Connections Health Solutions, LLC is the pioneer of behavioral health crisis care. The Company operates the two largest behavioral health crisis facilities in the nation and provides a range of services to help stabilize and treat people with mental health and substance use diagnoses. Connections` model emphasizes providing treatment in the least restrictive setting and has demonstrated improved quality and cost savings, including significantly reducing hospital admissions in Medicaid and behavioral health populations. For more information and crisis resources, please visit www.connectionshs.com. We believe that people do best when they don`t have to wait a long time to get what they need. As a result, we have created a culture in which we welcome everyone regardless of clinical complexity, provide intervention as quickly as possible, and partner with community support systems to maximize recovery. Our corporate mission is simple: to address any behavioral health need, at any time.
Peachtree Medical Billing is a Athens, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
International Medical Equipment is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.